September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Choroidal morphology and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy
Author Affiliations & Notes
  • Jihwan Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Seo Hee Kim
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • SungChul Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Christopher Seungkyu Lee
    Ophthalmology, Yonsei university college of medicine, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Jihwan Lee, None; Seo Hee Kim, None; SungChul Lee, None; Christopher Lee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4650. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jihwan Lee, Seo Hee Kim, SungChul Lee, Christopher Seungkyu Lee; Choroidal morphology and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4650.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The present study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor (VEGF) therapy.

Methods : Fifty eyes of 50 treatment-naïve patients with myopic CNV who underwent anti-VEGF monotherapy with at least 2 years of follow-up data were included. The cumulative incidence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression.

Results : The mean age was 52.34 years. A mean of 4.84 anti-VEGF injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated incidence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. CRA progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit.

Conclusions : CRA progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid with respect to the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-VEGF therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×